๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Adjuvant treatment of malignant melanoma: Where are we?

โœ Scribed by Paolo A. Ascierto; Stefania Scala; Alessandro Ottaiano; Ester Simeone; Ileana de Michele; Giuseppe Palmieri; Giuseppe Castello

Book ID
108110060
Publisher
Elsevier Science
Year
2006
Tongue
English
Weight
153 KB
Volume
57
Category
Article
ISSN
1040-8428

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Treatment of bulimia nervosa: Where are
Treatment of bulimia nervosa: Where are we and where are we going?
โœ Mitchell, James E. ;Agras, Stewart ;Wonderlich, Stephen ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› Wiley (John Wiley & Sons) ๐ŸŒ English โš– 104 KB ๐Ÿ‘ 1 views

## Abstract ## Objective: The purpose of this article is to review the extant treatment literature on bulimia nervosa and to offer suggestions for future research directions. ## Method: The available treatment studies regarding both pharmacotherapy and psychotherapy are reviewed. ## Results: B

Adjuvant immunotherapy of malignant mela
Adjuvant immunotherapy of malignant melanoma
โœ Gerard V. Aranha; Charles F. McKhann; Theodor B. Grage; Audolfur Gunnarsson; Ric ๐Ÿ“‚ Article ๐Ÿ“… 1979 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 561 KB
Adjuvant treatment of malignant melanoma
Adjuvant treatment of malignant melanoma with DTIC + estracyt or BCG
โœ Dr. Constantine P. Karakousis; Lawrence J. Emrich ๐Ÿ“‚ Article ๐Ÿ“… 1987 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 338 KB

Eighty-two patients with invasive malignant melanoma and no distant metastases were prospectively randomized following their surgical treatment to 1) observation; 2) chemotherapy with Dacarbazine (DTIC) 200 mg/M2 I.V. daily X 5 every 4 weeks and Estracyt 15 mg/kg orally daily for 1 year; and 3) immu